Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents

Bioorg Med Chem Lett. 2013 Feb 15;23(4):934-8. doi: 10.1016/j.bmcl.2012.12.063. Epub 2013 Jan 3.

Abstract

Based on known heterocyclic topoisomerase II inhibitors and anticancer agents, various indenoindolone derivatives were predicted as potential topoisomerase II-inhibiting anticancer agents. They are hydrazones, (thio)semicarbazones, and oximes of indenoindolones, and indenoindolols. These derivatives with suitable substitutions exhibited potent specific inhibition of human DNA TopoIIα while not showing inhibition of topoisomerase I and DNA intercalation, despite the fact that parent indenoindolones are known poor/moderate inhibitors of topoisomerase II. The potent topoisomerase II inhibitor indenoindolone derivatives exhibited good anticancer activities compared to etoposide and 5-fluorouracil, and relatively low toxicity to normal cells. These derivatizations of indenoindolones were found to result in enhancement of anticancer activities.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • DNA Topoisomerases, Type II / chemistry
  • DNA Topoisomerases, Type II / metabolism
  • Humans
  • Indoles / chemistry*
  • Indoles / pharmacology*
  • Indoles / therapeutic use
  • Models, Molecular
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology
  • Topoisomerase II Inhibitors / chemistry
  • Topoisomerase II Inhibitors / pharmacology*
  • Topoisomerase II Inhibitors / therapeutic use

Substances

  • Antineoplastic Agents
  • Indoles
  • Topoisomerase II Inhibitors
  • indenoindole
  • DNA Topoisomerases, Type II